🚀 VC round data is live in beta, check it out!
Yunnan Baiyao Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Yunnan Baiyao Group and similar public comparables like Regencell Bioscience, BridgeBio Pharma, Ascendis Pharma, Torrent Pharmaceuticals and more.
Yunnan Baiyao Group Overview
About Yunnan Baiyao Group
Yunnan Baiyao Group Co Ltd is engaged in the manufacturing and marketing of medicines, which include herbal products, daily health products, raw medicine, drug classics, and others.
Founded
1993
HQ
Employees
9.3K
Website
Financials (LTM)
EV
$13B
Yunnan Baiyao Group Financials
Yunnan Baiyao Group reported last 12-month revenue of $6B and EBITDA of $878M.
In the same LTM period, Yunnan Baiyao Group generated $2B in gross profit, $878M in EBITDA, and $772M in net income.
Revenue (LTM)
Yunnan Baiyao Group P&L
In the most recent fiscal year, Yunnan Baiyao Group reported revenue of $6B and EBITDA of $942M.
Yunnan Baiyao Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6B | XXX | $6B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $878M | XXX | $942M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $772M | XXX | $756M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Yunnan Baiyao Group Stock Performance
Yunnan Baiyao Group has current market cap of $14B, and enterprise value of $13B.
Market Cap Evolution
Yunnan Baiyao Group's stock price is $8.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $14B | -0.5% | XXX | XXX | XXX | $0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYunnan Baiyao Group Valuation Multiples
Yunnan Baiyao Group trades at 2.1x EV/Revenue multiple, and 14.3x EV/EBITDA.
EV / Revenue (LTM)
Yunnan Baiyao Group Financial Valuation Multiples
As of April 18, 2026, Yunnan Baiyao Group has market cap of $14B and EV of $13B.
Equity research analysts estimate Yunnan Baiyao Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yunnan Baiyao Group has a P/E ratio of 18.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14B | XXX | $14B | XXX | XXX | XXX |
| EV (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.3x | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBIT | 14.9x | XXX | 15.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | 18.7x | XXX | 19.1x | XXX | XXX | XXX |
| EV/FCF | 13.7x | XXX | 14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Yunnan Baiyao Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Yunnan Baiyao Group Margins & Growth Rates
Yunnan Baiyao Group's revenue in the last 12 month grew by 4%.
Yunnan Baiyao Group's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.1M for the same period.
Yunnan Baiyao Group's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yunnan Baiyao Group's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Yunnan Baiyao Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Yunnan Baiyao Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yunnan Baiyao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascendis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Torrent Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sino Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yunnan Baiyao Group M&A Activity
Yunnan Baiyao Group acquired XXX companies to date.
Last acquisition by Yunnan Baiyao Group was on XXXXXXXX, XXXXX. Yunnan Baiyao Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Yunnan Baiyao Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYunnan Baiyao Group Investment Activity
Yunnan Baiyao Group invested in XXX companies to date.
Yunnan Baiyao Group made its latest investment on XXXXXXXX, XXXXX. Yunnan Baiyao Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Yunnan Baiyao Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Yunnan Baiyao Group
| When was Yunnan Baiyao Group founded? | Yunnan Baiyao Group was founded in 1993. |
| Where is Yunnan Baiyao Group headquartered? | Yunnan Baiyao Group is headquartered in China. |
| How many employees does Yunnan Baiyao Group have? | As of today, Yunnan Baiyao Group has over 9K employees. |
| Who is the CEO of Yunnan Baiyao Group? | Yunnan Baiyao Group's CEO is Ming Dong. |
| Is Yunnan Baiyao Group publicly listed? | Yes, Yunnan Baiyao Group is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Yunnan Baiyao Group? | Yunnan Baiyao Group trades under 000538 ticker. |
| When did Yunnan Baiyao Group go public? | Yunnan Baiyao Group went public in 1993. |
| Who are competitors of Yunnan Baiyao Group? | Yunnan Baiyao Group main competitors are Regencell Bioscience, BridgeBio Pharma, Ascendis Pharma, Torrent Pharmaceuticals. |
| What is the current market cap of Yunnan Baiyao Group? | Yunnan Baiyao Group's current market cap is $14B. |
| What is the current revenue of Yunnan Baiyao Group? | Yunnan Baiyao Group's last 12 months revenue is $6B. |
| What is the current revenue growth of Yunnan Baiyao Group? | Yunnan Baiyao Group revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Yunnan Baiyao Group? | Current revenue multiple of Yunnan Baiyao Group is 2.1x. |
| Is Yunnan Baiyao Group profitable? | Yes, Yunnan Baiyao Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yunnan Baiyao Group? | Yunnan Baiyao Group's last 12 months EBITDA is $878M. |
| What is Yunnan Baiyao Group's EBITDA margin? | Yunnan Baiyao Group's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Yunnan Baiyao Group? | Current EBITDA multiple of Yunnan Baiyao Group is 14.3x. |
| What is the current FCF of Yunnan Baiyao Group? | Yunnan Baiyao Group's last 12 months FCF is $918M. |
| What is Yunnan Baiyao Group's FCF margin? | Yunnan Baiyao Group's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Yunnan Baiyao Group? | Current FCF multiple of Yunnan Baiyao Group is 13.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.